CAS: 168555-66-6; Disodium (Z)-2-Methoxy-5-(3,4,5-Trimethoxystyryl)Phenyl Phosphate

该化合物是一种小分子,主要用作抗癌剂,主要起到血管干扰剂的作用,目的是瞄准和干扰肿瘤的血液供应,从而抑制肿瘤的生长,助长肿瘤细胞死亡;该化合物是活性剂Fosbretabulin的精液,它来自天然产品Byrestatin A-4;Fosbretabulin di钠通常通过静脉注射进行,并在包括高级固态肿瘤在内的各种癌症临床试验中受到调查;其行动机制涉及内耳细胞细胞细胞的细胞细胞细胞不稳定,导致肿瘤血管血管崩溃;二盐的盐状增加了其溶性与生物利用率;与许多抗癌疗法一样,潜在的副作用可能包括血管并发症,疲劳和胃肠扰动;持续的研究继续与其他治疗剂一起探索其有效性和安全性.

结构式图片

合成工艺路线路线简述

    海关参考信息

    专利信息


    专利号:US-7935704-B2
    优先权日:2003-08-01
    标 题 :Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
    发明人:PALLADINO MICHAEL A; LLOYD GEORGE KENNETH; HAYASHI YOSHIO; NICHOLSON BENJAMIN
    权利人:NEREUS PHARMACEUTICALS INC
    摘要:Compounds represented by the following structure (I) are disclosed: n nas are methods for making such compounds, wherein said methods comprise reacting a diacyldiketopiperazine with a first aldehyde to produce an intermediate compound; and reacting the intermediate compound with a second aldehyde to produce the class of compounds with the generic structure, where the first aldehyde and the second aldehydes are selected from the group consisting of an oxazolecarboxaldeyhyde, imidazolecarboxaldehyde, a benzaldehyde, imidazolecarboxaldehyde derivatives, and benzaldehyde derivatives, thereby forming the above compound wherein R 1 , R 1 ′, R 1 ″, R 2 , R 3 , R 4 , R 5 , and R 6 , X 1 and X 2 , Y, Z, Z 1 , Z 2 , Z 3 , and Z 4 may each be separately defined in a manner consistent with the accompanying description. Compositions and methods for treating vascular proliferation are also disclosed.

    专利号:US-2005197344-A1
    优先权日:2003-08-01
    标题 :Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof

    专利号:CA-2553630-A1
    优先权日:2004-02-04
    标 题:Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof

    专利号:US-6392055-B1
    优先权日:2000-07-19
    标 题 :Synthesis and biological evaluation of analogs of the antimitotic marine natural product curacin A
    发明人:WIPF PETER; REEVES JONATHAN T; DAY BILLY W; BALACHANDRAN RAGHAVAN
    权利人:UNIV PITTSBURGH
    摘要:The present invention provides an efficient synthetic strategy for the preparation of analogs that incorporate important structural elements of the marine natural product curacin A, the compositions and various uses of the compositions. The most active of these compounds at nanomolar concentrations inhibit tubulin polymerization, show growth inhibition activity, inhibited colchicines binding to tubulin and block mitotic progression. The compounds of the present invention represent some of the most potent synthetic curacin A analogs synthesized, with an activity profile rivaling that of the natural product despite the simplified structure, greater water solubility, and increased chemical stability.

    专利号:AU-2005212399-B2
    优先权日:2004-02-04
    标题 :Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof

    专利号:WO-2005077940-A1
    优先权日:2004-02-04
    标题 :Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
    杭州瑞树生化有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.great-forest.com
    企业联系电话:0571-28313180,28313181👤
    📞杭州瑞树生化有限公司 ⚠️参考联系方式
    联系人:李小玲
    电话:0571-28313180,28313181
    手机:17767135330
    传真:0571-28313182
    邮箱:info@great-forest.com
    通信地址: 杭州市余杭区仓前镇文一西路1378号,F座,909-913室
    邮编: 311121
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:杭州市余杭区仓前镇文一西路1378号,F座,909-913室
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Sosa JA, Balkissoon J, Lu SP, Langecker P, Elisei R, Jarzab B, Bal CS, Marur S, Gramza A, Ondrey F. Thyroidectomy followed by fosbretabulin (CA4P) combination regimen appears to suggest improvement in patient survival in anaplastic thyroid cancer. Surgery. 2012 Dec;152(6):1078-87. doi: 10.1016/j.surg.2012.08.036. Review. doi: 10.1016/j.bpj.2012.03.063.
    3: Nathan P, Zweifel M, Padhani AR, Koh DM, Ng M, Collins DJ, Harris A, Carden C, Smythe J, Fisher N, Taylor NJ, Stirling JJ, Lu SP, Leach MO, Rustin GJ, Judson I. Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer. Clin Cancer Res. 2012 Jun 15;18(12):3428-39. doi: 10.1158/1078-0432.CCR-11-3376. Epub 2012 May 29. doi: 10.1038/sj.bjc.6605650. Epub 2010 Apr 13.
    5: Siemann DW, Chaplin DJ, Walicke PA. A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P). Expert Opin Investig Drugs. 2009 Feb;18(2):189-97. doi: 10.1517/13543780802691068 . Review.

    合成参考文献


    参考文献:10.1021/jm200454y
    摘要:Flynn BL, Gill GS, Grobelny DW, Chaplin JH, Paul D, Leske AF, Lavranos TC, Chalmers DK, Charman SA, Kostewicz E, Shackleford DM, Morizzi J, Hamel E, Jung MK, Kremmidiotis G. Discovery of 7-hydroxy-6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzo[b]furan (BNC105), a tubulin polymerization inhibitor with potent antiproliferative and tumor vascular disrupting properties. J Med Chem. 2011 Sep 08;54(17):6014–27.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知